Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
TALACEN is an oral small-molecule tablet approved in 1982 by Sanofi under NDA. The product's specific mechanism of action, pharmacologic class, and approved indications are not publicly documented in available data. Generic information is not available.
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting team downsizing and transition planning is underway.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero job postings linked to TALACEN indicate minimal hiring or career mobility on this product. Working on a LOE-approaching asset requires focus on defensive strategy, generic transition planning, and risk management rather than growth initiatives.
Worked on TALACEN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.